OncoCyte Corporation (AMEX:OCX) is set to announce third quarter earning results on Thursday 12th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, OCX to report 3Q20 loss of $ 0.09 per share from revenue of $ 0.37 million.
For the full year, analysts anticipate top line of $ 1.35 million, while looking forward to loss of $ 0.45 per share bottom line.
Previous Quarter Performance
OncoCyte Corporation communicated loss for the second quarter of $ 0.14 per share, from the revenue of $ 0.14 million. Wall street analysts are predicting, OCX to report 2Q20 loss of $ 0.10 per share from revenue of $ 0.05 million. The bottom line results missed street analysts by $ 0.04 or 40 percent, at the same time, top line results outshined analysts by $ 0.09 million or 180.00 percent.
Stock Performance
Shares of OncoCyte Corporation traded up $ 0.05 or 2.94 percent on Wednesday, reaching $ 1.75 with volume of 336.80 thousand shares. OncoCyte Corporation has traded high as $ 1.75 and has cracked $ 1.66 on the downward trend
The closing price of $ 1.75, representing a 47.83 % increase from the 52 week low of $ 1.15 and a 51.57 % decrease over the 52 week high of $ 3.51.
The company has a market capital of $ 117.69 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
OncoCyte Corporation will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-9716 Toll Free or 201-493-6779 Toll Number, when prompted, enter passcode 13709425 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.oncocyte.com
OncoCyte Corporation engages in the development and commercialization of non-invasive blood-based diagnostic tests for the early detection of cancer. The company is developing DetermaVu, a non-invasive molecular lung cancer confirmatory diagnostic that is administered to patients as a blood test. It also develops diagnostic tests based on liquid biopsies for detecting breast cancer.
